Aim: To observe the humoral immuneresponse in Rhesus monkey induced by Abeta42 peptide vaccination.
Methods: Five male Rhesus monkeys were received intramuscular injection of Abeta42 peptide vaccine at 0, 2nd, 6th, 10th, 14th, 18th, 22th week. The titers and Ig subclasses of the serum anti-Abeta42 antibody were measured by ELISA. The specificity of the anti-Abeta42 antibody was determined by Western blot. The recognition of Abeta plaques in Tg2576-transgenic mouse brain tissue by anti-Abeta42 serum were detected by immunohistochemical staining.
Results: At the 8th week after the vaccination, the serum anti-Abeta42 antibody was detected. The titers of the antibody increased with times of booster inoculation and reached 1:4,320 at the 24th week, then decreased. The produced antibodies were mainly IgG1 and IgG2(IgG2/IgG1>1). The anti-Abeta42 antibody had high specificity. The Abeta plaques in Tg2576-transgenic mouse brain tissue were recognized by the antisera.
Conclusion: Abeta42 peptide vaccine can induce effectively specific humoral immuneresponse in Rhesus monkey.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Transient interactions between the fuzzy coat and the cross-β core of brain-derived Aβ42 filaments.
Sci Adv
January 2025
Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.
Several human disorders, including Alzheimer's disease (AD), are characterized by the aberrant formation of amyloid fibrils. In many cases, the amyloid core is flanked by disordered regions, known as fuzzy coat. The structural properties of fuzzy coats, and their interactions with their environments, however, have not been fully described to date.
View Article and Find Full Text PDFBlarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.
J Prev Alzheimers Dis
January 2025
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Electronic address:
Background: There are no approved oral disease-modifying treatments for Alzheimer's disease (AD).
Objectives: The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through restoration of cellular homeostasis including autophagy enhancement.
Design: ANAVEX2-73-AD-004 was a randomized, double-blind, placebo-controlled, 48-week Phase IIb/III trial.
Association and multimodal model of retinal and blood-based biomarkers for detection of preclinical Alzheimer's disease.
Alzheimers Res Ther
January 2025
School of Optometry, University of Alabama at Birmingham, Birmingham, AL, US.
Background: The potential diagnostic value of plasma amyloidogenic beta residue 42/40 ratio (Aβ42/Aβ40 ratio), neurofilament light (NfL), tau phosphorylated at threonine-181 (p-tau181), and threonine-217 (p-tau217) has been extensively discussed in the literature. We have also previously described the association between retinal biomarkers and preclinical Alzheimer's disease (AD). The goal of this study was to evaluate the association, and a multimodal model of, retinal and plasma biomarkers for detection of preclinical AD.
View Article and Find Full Text PDFPlasma S100β is a predictor for pathology and cognitive decline in Alzheimer's disease.
Fluids Barriers CNS
January 2025
Sanders-Brown Center on Aging, College of Medicine, University of Kentucky, 760 Press Ave, 124 HKRB, Lexington, KY, 40536-0679, USA.
Background: Blood-brain barrier dysfunction is one characteristic of Alzheimer's disease (AD) and is recognized as both a cause and consequence of the pathological cascade leading to cognitive decline. The goal of this study was to assess markers for barrier dysfunction in postmortem tissue samples from research participants who were either cognitively normal individuals (CNI) or diagnosed with AD at the time of autopsy and determine to what extent these markers are associated with AD neuropathologic changes (ADNC) and cognitive impairment.
Methods: We used postmortem brain tissue and plasma samples from 19 participants: 9 CNI and 10 AD dementia patients who had come to autopsy from the University of Kentucky AD Research Center (UK-ADRC) community-based cohort; all cases with dementia had confirmed severe ADNC.
Betaamyloid protein regulates miR15a and activates Bag5 to influence neuronal apoptosis in Alzheimers disease.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
July 2024
Department of Neurology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Objectives: The prevalence of Alzheimer's disease (AD) is increasing globally, however its pathogenesis is still unclear. The evidence showed that the progression of AD was closely related to the apoptosis of nerve cells. This study amis to explore the role and specific mechanism of miR-15a and Bag5 in the apoptosis of nerve cells induced by beta-amyloid protein (Aβ) in AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!